title: Future of immunotherapy drug combinations and biomarkers.
authors.forename: Charlie
authors.initials: C
authors.lastname: Schmidt
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D015415:Biomarkers; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D007211:Indoles / Q000627:therapeutic use; D000074324:Ipilimumab; D008565:Membrane Proteins / Q000276:immunology; D013449:Sulfonamides / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects; D014020:Tissue Extracts / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015415:Biomarkers; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D007211:Indoles; D000074324:Ipilimumab; D008565:Membrane Proteins; D013449:Sulfonamides; D014020:Tissue Extracts; D000077484:Vemurafenib; C511774:sipuleucel-T